Genetic testing is powerful and selectively useful. A handful of panels have clear clinical value when ordered in the right patient. Many others are either too early in their evidence base, too general in their predictions, or too psychologically heavy for patients who have not had a pre-test counseling conversation. At TrufaMED, genetic screening in Miami is delivered by board-certified physicians inside a Joint Commission-accredited clinical setting — with integrated pre-test counseling, on-site draws, and a plan for what to do with the result before it ever comes back.
The genetic screens with the strongest clinical utility in 2026 are hereditary cancer panels (BRCA1, BRCA2, Lynch syndrome) for patients with qualifying family history, expanded carrier screening for couples planning conception, Galleri multi-cancer early detection for patients 40 and older with family cancer history, and GeneSight pharmacogenomics for psychiatric medication selection. APOE for Alzheimer’s risk and CCR5 for HIV resistance are available but require explicit pre-test counseling. Polygenic risk scores are promising but still supplementary.
Direct-to-consumer genetic testing has expanded into a very crowded marketplace. Ancestry panels, wellness panels, "DNA-guided" nutrition, fitness, and longevity reports all claim to be genetic. Most of them are built on thin evidence and rarely change clinical management. This post focuses exclusively on the genetic panels that a physician will actually act on. If a result would not change your prevention plan, your treatment plan, or a family planning decision, the test should be deferred or declined.
TrufaMED’s preventive care program integrates genetic screening with biomarker data and family history review. The result is a single coordinated risk profile that a physician can act on, rather than a stack of disconnected test reports.
Galleri is a blood-based multi-cancer early detection (MCED) test developed by Grail. It uses a methylation signature in cell-free DNA to flag a cancer signal and, when positive, predict the most likely tissue of origin. The panel detects signals associated with more than 50 cancer types — including pancreatic, ovarian, kidney, liver, stomach, and head and neck cancers that currently have no general-population screening protocol.
What Galleri does well: it adds a complementary screen to the five cancers with established population screening (breast, colon, cervix, prostate, and — in eligible smokers — lung). That matters because those five together account for roughly half of cancer deaths; the other half come from cancers without a screening pathway.
What Galleri does not do: it does not replace mammography, colonoscopy, cervical screening, or low-dose CT. A negative Galleri does not mean cancer has been ruled out. A positive Galleri requires structured diagnostic workup — directed imaging based on the predicted tissue of origin, and sometimes a confirmatory biopsy. Detection sensitivity is higher for advanced cancers and lower for earliest-stage disease, which is where the greatest benefit would theoretically lie. The evidence base is evolving and long-term mortality benefit is being studied in large trials.
TrufaMED performs Galleri draws on-site and integrates the result into the physician consultation. The test is typically recommended for adults over 50, adults over 40 with first-degree cancer family history, and any adult who wants comprehensive cancer surveillance beyond the five-cancer standard screening set. Pricing is $1,150 self-pay.
GeneSight is a buccal swab panel that maps variants in genes encoding the enzymes responsible for psychiatric medication metabolism — most importantly CYP2D6 and CYP2C19, plus CYP1A2, CYP3A4, and serotonin transporter variants (SLC6A4, HTR2A).
The clinical utility is most established for patients who have tried one or two antidepressants or antipsychotics and experienced either a significant side-effect burden or a partial response. In those patients, GeneSight can identify likely poor metabolizers or ultra-rapid metabolizers of specific drugs and steer selection toward medications the patient is more likely to tolerate and benefit from.
What GeneSight does not do: diagnose depression, anxiety, or any psychiatric condition. It does not predict which medication will produce remission. It does not replace the iterative trial-and-adjust process of pharmacotherapy. It is an adjunct, not a replacement for clinical judgment.
TrufaMED’s physicians use GeneSight selectively for concierge members and preventive care patients who have a history of psychiatric medication intolerance or treatment-resistant symptoms, with coordinated care back to the treating psychiatric provider when relevant.
APOE is the best-studied genetic modulator of late-onset Alzheimer’s disease risk. A single copy of the APOE4 allele roughly triples lifetime Alzheimer’s risk; two copies raise it roughly eight to twelve times. About 15 to 25 percent of the population carries at least one APOE4 copy.
APOE testing is controversial, and appropriately so. There is no definitive preventive pharmacotherapy for Alzheimer’s disease yet approved for asymptomatic APOE4 carriers. Lifestyle interventions — aerobic exercise, Mediterranean dietary pattern, sleep optimization, vascular risk factor control, hearing correction, cognitive engagement — are recommended for everyone regardless of APOE status. Some patients want to know their status to intensify these behaviors; some patients do not want to know, and would rather not carry the psychological weight without a clear actionable intervention.
TrufaMED requires explicit pre-test counseling, informed consent, and a documented conversation about psychological implications and insurance considerations (life, disability, and long-term care insurance are not covered by federal GINA protections) before performing APOE testing. It is available to patients who request it after that conversation. It is not part of any standard panel.
The CCR5 receptor on CD4+ T cells is the primary entry point for most HIV strains. The CCR5-delta-32 mutation, when inherited homozygously, confers near-complete resistance to CCR5-tropic HIV. Heterozygous carriers may have slower progression if infected.
CCR5 testing is occasionally requested by patients out of scientific interest or in the context of detailed family planning. It does not replace standard HIV prevention — condom use, PrEP where indicated, and regular testing services. TrufaMED will perform the test on request with appropriate counseling that a positive result is not protective against all HIV strains (CXCR4-tropic virus uses a different receptor) and does not remove the need for standard prevention.
This is the category of genetic testing with the clearest, oldest, and most actionable evidence base. Hereditary cancer gene panels test for pathogenic variants in genes that significantly elevate lifetime cancer risk: BRCA1, BRCA2 (breast, ovarian, pancreatic, prostate), Lynch syndrome genes (MLH1, MSH2, MSH6, PMS2 — colorectal, endometrial, others), TP53 (Li-Fraumeni, many cancers), PALB2, ATM, CHEK2, PTEN (Cowden), CDKN2A (melanoma, pancreatic), and more.
Guideline-based indications include: breast cancer at any age in a first-degree relative under 50, male breast cancer, ovarian cancer at any age, pancreatic cancer in a close relative, colorectal or endometrial cancer under 50, multiple primary cancers in one family member, Ashkenazi Jewish ancestry with any family breast or ovarian history, and constellation patterns suggesting Lynch syndrome.
A positive result typically triggers enhanced surveillance (annual breast MRI in addition to mammography for BRCA1/2 carriers, earlier and more frequent colonoscopy for Lynch carriers), risk-reducing pharmacotherapy discussion (tamoxifen in some settings), and risk-reducing surgery discussion (bilateral salpingo-oophorectomy after childbearing for BRCA1/2 carriers). It also triggers cascade testing — identifying at-risk relatives and offering them testing.
A negative result in a family with a known pathogenic variant is informative. A negative result in a family that has never had a known variant identified ("uninformative negative") does not eliminate hereditary risk. Physician interpretation is essential.
Expanded carrier screening tests both prospective parents for heterozygous mutations in recessive disease genes — typically hundreds of conditions including cystic fibrosis, spinal muscular atrophy, sickle cell disease, Tay-Sachs, Canavan, fragile X, and many others. A single carrier result does not affect the individual’s health. What matters is whether both partners carry a mutation in the same gene: if so, each pregnancy has a 25 percent chance of being affected.
Carrier screening is offered to couples considering conception, ideally before pregnancy when the full range of options (preimplantation genetic diagnosis, donor gametes, prenatal testing) is available. It is often covered by insurance when ordered in a family-planning context.
Polygenic risk scores (PRS) sum the small individual effects of many common variants to produce a composite risk estimate for conditions such as coronary artery disease, type 2 diabetes, atrial fibrillation, breast cancer, and prostate cancer. The best-developed PRS are for CAD and type 2 diabetes.
PRS can identify a subset of patients whose polygenic load places them at meaningfully elevated risk even in the absence of other classical risk factors. In a CAD context, this may shift statin therapy decisions earlier. In a type 2 diabetes context, it may intensify lifestyle counseling.
The caveats are real. Most PRS have been developed in populations of European ancestry and underperform in non-European populations, which is a meaningful limitation in a diverse city like Miami. The effect sizes are modest compared to traditional risk calculators. TrufaMED treats PRS as a supplement to — not a replacement for — the ASCVD risk calculator, biomarker data, and family history.
Direct-to-consumer panels marketed as "DNA-guided nutrition," "DNA-guided fitness," "DNA-guided supplements," and similar are almost entirely without evidence for clinical action. The underlying variants often have small or contested effect sizes, and the dietary and fitness recommendations produced from them are generally indistinguishable from standard evidence-based advice. Most physicians will not change a clinical plan based on these panels.
If a patient arrives with DTC results in hand, TrufaMED will review them in the physician consultation, confirm any clinically relevant findings (such as a BRCA-raw-data flag that needs confirmation in a clinical laboratory), and move on to the panels that actually change management.
Genetic testing is one input in a larger preventive and longitudinal framework. For concierge members, genetic results are integrated with the baseline biomarker panel, family history, and physician assessment into a unified risk profile. For preventive-care patients, the same integration applies at a la carte scale.
The intake and follow-up pathway:
Federal GINA (Genetic Information Nondiscrimination Act) protects against employment discrimination and discrimination by most health insurers. It does not cover life insurance, disability insurance, or long-term care insurance. A genetic result in the medical record could influence underwriting for those products in the future. Patients are counseled on this reality before testing, and for some tests (particularly APOE) may elect not to include the result in the electronic record.
Pre-test counseling is the standard of care for hereditary cancer panels, expanded carrier screening, and APOE. TrufaMED provides pre-test counseling in the physician consultation and engages a certified genetic counselor for complex cases.
Patients often pair genetic screening with a broader preventive evaluation. See executive physical in Miami Beach for the comprehensive annual framework, and longevity medicine in Miami Beach for the healthspan-optimization context. Micronutrient correction identified on baseline labs is addressed through IV therapy when oral repletion is inadequate.
Galleri is a multi-cancer early detection blood test that screens for a methylation signature associated with more than 50 types of cancer. It detects cell-free DNA shed by tumors. A positive result predicts a likely cancer signal and a probable tissue of origin, which then directs confirmatory imaging or biopsy. A negative result does not replace standard screening such as mammography, colonoscopy, or low-dose lung CT.
GeneSight is a pharmacogenomic panel that maps variants in genes that metabolize psychiatric medications, most notably CYP2D6 and CYP2C19. Evidence is strongest for guiding selection and dosing of some antidepressants. It does not replace clinical judgment or diagnose depression or anxiety. It is most useful after a first or second antidepressant trial has produced side effects or poor response.
APOE testing identifies the number of APOE4 alleles a person carries, which modulates lifetime Alzheimer’s risk. The test is controversial because there is no preventive pharmacotherapy that definitively alters the trajectory, and a positive result can carry psychological and insurance implications. TrufaMED does not perform APOE testing without pre-test genetic counseling and explicit documented informed consent.
CCR5 is a receptor on the surface of immune cells. A homozygous CCR5-delta-32 mutation confers resistance to most strains of HIV. The test is not a standard of care screen. It is sometimes requested by patients out of scientific curiosity or for fertility-related decisions. It does not replace standard HIV prevention strategies.
Hereditary cancer screening (BRCA1, BRCA2, Lynch syndrome and others) is indicated for patients with a personal or family history that meets guideline criteria: early-onset cancer in a first-degree relative, male breast cancer, ovarian cancer, multiple primary cancers in one family member, Ashkenazi Jewish ancestry with family breast or ovarian history, or a cluster of cancers on the same side of the family.
Carrier screening tests for heterozygous mutations in recessive genes. A positive carrier result typically does not affect the individual’s health but is important for family planning: if both parents carry mutations in the same gene, offspring have a 25 percent chance of being affected. Carrier screening is offered to couples considering conception.
Polygenic risk scores (PRS) combine the effects of many small-effect variants to estimate risk for conditions such as coronary artery disease, type 2 diabetes, and atrial fibrillation. The science is improving. Current clinical utility is modest and population-dependent. TrufaMED uses PRS as a complement to, not a replacement for, traditional risk calculators and biomarker data.
Hereditary cancer screening is often covered when a patient meets clinical criteria documented in the physician note. Carrier screening is commonly covered for couples planning conception. Galleri, GeneSight, and polygenic risk panels are typically self-pay. Coverage varies significantly by plan and TrufaMED confirms benefits before ordering.
Genetic results become part of the medical record. Federal GINA legislation prevents employment and most health insurance discrimination but does not cover life, disability, or long-term care insurance. Patients are counseled on privacy implications before testing and can choose which results they wish to receive, including whether to see APOE status.
Pre-test counseling is standard for hereditary cancer testing, expanded carrier screening, and APOE. TrufaMED provides pre-test counseling in the physician consultation and refers to a certified genetic counselor when the clinical picture warrants extended risk-benefit discussion.
Begin your genetic screening consultation. Physician-led. Joint Commission accredited. Pre-test counseling and a plan before any sample is drawn. Learn more through our concierge services or our preventive care program. Meet the clinical team.
TrufaMED Urgent Care and Concierge Medicine is located at 9445 Harding Avenue, Surfside, FL 33154 — directly adjacent to Miami Beach. Open Monday to Friday 9 AM to 9 PM, Saturday 11 AM to 11 PM, and Sunday 12 PM to 8 PM. Board-certified physicians on shift every day. Same-day urgent care visits available for acute concerns.
Serving These Areas
Copyright © 2026 TrufaMED Urgent Care
